How should I manage a patient with a PHQ‑9 (Patient Health Questionnaire‑9) score of 22 and a GAD‑7 (Generalized Anxiety Disorder‑7) score of 19?

Management of Severe Depression and Anxiety (PHQ-9: 22, GAD-7: 19)

This patient requires immediate psychiatric referral and initiation of both pharmacologic and non-pharmacologic treatment, as these scores indicate severe depression (PHQ-9 ≥20) and severe anxiety (GAD-7 ≥15).

Immediate Actions Required

1. Assess for Safety First

• Directly evaluate suicidal ideation and intent - PHQ-9 item 9 specifically addresses thoughts of self-harm
• If any risk of harm to self or others exists, initiate emergency psychiatric evaluation immediately 1
• Facilitate a safe environment and implement harm-reduction interventions 1

2. Conduct Diagnostic Assessment

With scores this severe, you must perform a comprehensive diagnostic evaluation to:

• Confirm the presence of major depressive disorder and/or generalized anxiety disorder
• Rule out medical causes: thyroid dysfunction, medication side effects (e.g., interferon, corticosteroids), substance use, electrolyte imbalances, or delirium 1
• Assess for comorbid conditions and functional impairment
• Identify specific stressors and risk factors 1

The guideline evidence is clear: when moderate to severe or severe symptomatology is detected through screening, further diagnostic assessment is mandatory to identify the nature and extent of symptoms and presence of mood disorders 1.

Treatment Initiation

3. Refer to Mental Health Specialist

Referral to a psychiatrist, psychologist, or equivalently trained professional is necessary at these severity levels 1. This is not optional - the clinical team must make this referral as a shared responsibility.

4. **Start Treatment Immediately (Don't Wait for Specialist)

Pharmacologic Treatment:

• Initiate an antidepressant medication immediately
• Select based on:
  • Side effect profile and tolerability
  • Potential drug interactions with current medications
  • Previous treatment response (if applicable) 1
• No specific antidepressant is superior to another per guidelines, but starting treatment promptly is critical 1

Non-Pharmacologic Treatment:

• Arrange psychotherapy (cognitive-behavioral therapy, psychoeducational therapy, or other evidence-based modalities) 1
• These interventions should be delivered by appropriately trained individuals 1
• Consider combined pharmacologic and psychotherapeutic approaches for optimal management 1

Clinical Context and Interpretation

Understanding the Scores:

• PHQ-9 = 22: This falls in the severe depression range (scores ≥20 indicate severe depression) 1
• GAD-7 = 19: This indicates severe anxiety (scores ≥15 represent severe anxiety levels) 1

The GAD-7 cutoff of ≥19 specifically suggests moderate anxiety per some interpretations 1, but given the score is well above the severe threshold of ≥15, this represents clinically significant severe anxiety requiring intervention.

Important Considerations:

Comorbidity: The presence of both severe depression and severe anxiety is common and requires addressing both conditions 2. Research shows that 72.7% of anxiety interventions also examined comorbid depressive symptoms, with 62.5% being effective in reducing both 2.

Somatic vs. Cognitive Symptoms: Recent evidence suggests that both PHQ-9 and GAD-7 have two-factor structures (cognitive-affective and somatic symptoms) 3, 4. Pay attention to whether symptoms are predominantly somatic (which might suggest medical causes) or cognitive-affective.

Measurement Considerations: Be aware that subtle differences in how these questionnaires are administered can influence scores 5, but scores this elevated are clinically significant regardless of administration variability.

Follow-Up Plan

• Reassess within 1-2 weeks after treatment initiation
• Monitor treatment response using repeated PHQ-9 and GAD-7 scores
• Adjust treatment based on response and tolerability
• Ensure psychiatric follow-up is established
• Continue monitoring for safety throughout treatment

Critical Pitfalls to Avoid

1. Do not delay treatment waiting for specialist appointment - start pharmacotherapy immediately
2. Do not miss medical causes - always rule out thyroid disease, medications, substances, and delirium
3. Do not treat in isolation - these severity levels require specialist involvement
4. Do not ignore safety assessment - always evaluate suicide risk with PHQ-9 scores this high
5. Do not use questionnaires alone - these are screening tools that must be followed by clinical diagnostic assessment 1